05:22 AM EDT, 09/30/2026 (MT Newswires) -- H. Lundbeck (HLUN-A.CO, HLUN-B.CO) is working with advisers to evaluate its potential acquisition of US drugmaker Xeris Biopharma, Bloomberg News reported Tuesday, citing people familiar with the matter. However, there is no assurance that the Danish biopharmaceutical company will pursue a deal, the sources added. H. Lundbeck and Xeris Biopharma did not immediately respond to requests for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.